Universal Beteiligungs und Servicegesellschaft mbH Has $14.11 Million Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Universal Beteiligungs und Servicegesellschaft mbH reduced its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 8.7% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 124,682 shares of the medical equipment provider's stock after selling 11,949 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.06% of Zimmer Biomet worth $14,112,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of ZBH. Garde Capital Inc. bought a new stake in Zimmer Biomet during the first quarter worth $29,000. Menard Financial Group LLC bought a new stake in Zimmer Biomet during the fourth quarter worth $30,000. Washington Trust Advisors Inc. bought a new stake in Zimmer Biomet during the first quarter worth $30,000. Columbia River Financial Group LLC bought a new stake in Zimmer Biomet during the first quarter worth $30,000. Finally, Accredited Wealth Management LLC bought a new stake in Zimmer Biomet during the fourth quarter worth $36,000. 88.89% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Wells Fargo & Company decreased their target price on Zimmer Biomet from $113.00 to $98.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. Morgan Stanley decreased their target price on Zimmer Biomet from $115.00 to $95.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. JPMorgan Chase & Co. cut their price target on Zimmer Biomet from $128.00 to $105.00 and set an "overweight" rating for the company in a research note on Tuesday, May 6th. Truist Financial set a $101.00 price target on Zimmer Biomet in a research note on Tuesday, May 6th. Finally, JMP Securities cut their target price on Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating for the company in a research note on Wednesday, May 7th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, Zimmer Biomet presently has an average rating of "Hold" and an average price target of $111.39.

Insiders Place Their Bets

In related news, insider Sang Yi sold 1,000 shares of Zimmer Biomet stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $95.00, for a total transaction of $95,000.00. Following the completion of the sale, the insider directly owned 20,424 shares of the company's stock, valued at $1,940,280. The trade was a 4.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.39% of the stock is owned by corporate insiders.

Zimmer Biomet Stock Performance

NYSE ZBH traded up $0.72 on Friday, hitting $97.59. The stock had a trading volume of 1,068,261 shares, compared to its average volume of 1,849,641. Zimmer Biomet Holdings, Inc. has a one year low of $89.22 and a one year high of $116.71. The company's 50-day moving average is $93.20 and its two-hundred day moving average is $100.64. The company has a quick ratio of 1.46, a current ratio of 2.44 and a debt-to-equity ratio of 0.53. The stock has a market cap of $19.31 billion, a price-to-earnings ratio of 21.59, a P/E/G ratio of 2.26 and a beta of 0.71.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its earnings results on Monday, May 5th. The medical equipment provider reported $1.81 EPS for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. The firm had revenue of $1.91 billion for the quarter, compared to the consensus estimate of $1.89 billion. Zimmer Biomet had a return on equity of 12.73% and a net margin of 11.86%. The business's quarterly revenue was up 1.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.94 earnings per share. On average, analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Thursday, June 26th will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.98%. The ex-dividend date of this dividend is Thursday, June 26th. Zimmer Biomet's dividend payout ratio (DPR) is currently 21.24%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.